Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Short Interest Update

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) was the target of a large growth in short interest in April. As of April 30th, there was short interest totaling 523,399 shares, a growth of 363.6% from the April 15th total of 112,896 shares. Based on an average daily volume of 4,873,175 shares, the days-to-cover ratio is currently 0.1 days. Currently, 6.0% of the shares of the stock are short sold.

Analysts Set New Price Targets

Several brokerages recently commented on CPIX. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen upgraded shares of Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cumberland Pharmaceuticals presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Several large investors have recently made changes to their positions in CPIX. Dimensional Fund Advisors LP grew its holdings in Cumberland Pharmaceuticals by 1.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company’s stock worth $898,000 after acquiring an additional 4,081 shares during the last quarter. Two Sigma Investments LP lifted its position in Cumberland Pharmaceuticals by 16.5% during the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,326 shares during the period. Geode Capital Management LLC boosted its stake in Cumberland Pharmaceuticals by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after acquiring an additional 5,653 shares during the last quarter. Perceptive Advisors LLC bought a new position in Cumberland Pharmaceuticals during the 4th quarter worth approximately $1,358,000. Finally, Bridgeway Capital Management LLC boosted its stake in Cumberland Pharmaceuticals by 2.3% during the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after acquiring an additional 4,200 shares during the last quarter. Institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Stock Performance

Shares of Cumberland Pharmaceuticals stock traded up $0.39 on Friday, reaching $5.31. The stock had a trading volume of 188,051 shares, compared to its average volume of 732,355. The business’s 50-day moving average price is $3.50 and its two-hundred day moving average price is $3.48. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.84 and a current ratio of 0.95. Cumberland Pharmaceuticals has a fifty-two week low of $1.85 and a fifty-two week high of $6.26. The stock has a market cap of $79.47 million, a P/E ratio of -10.83 and a beta of -0.06.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The firm had revenue of $9.13 million during the quarter, compared to analysts’ expectations of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 17.60% and a negative return on equity of 12.01%.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.